CardioExchange Archive

CardioExchange, an NEJM practice community for medical professionals dedicated to improving cardiac patient care, was active from 2009 to 2015. CardioExchange fostered discussion between clinicians from across the globe.

August 26th, 2010

Getting Ready for the ESC

The ESC heart has arrived in Stockholm! #esc10 on TwitpicThe annual meeting of the European Society of Cardiology starts this weekend in Stockholm, and CardioExchange will be there. Associate Editor Anju Nohria will be blogging from the meeting, and I’ll be covering the most important news stories. Here are a few of the most-anticipated, late-breaking clinical trials. (Click here to search the program.)

29 Aug 2010

  • ALPHA OMEGA: Effect of low doses of n-3 fatty acids on cardiovascular diseases in post-MI patients. D Kromhout (Wageningen, NL) • Discussant:  L Tavazzi (Cotignola, IT)

30 Aug 2010

  • ATOLL: An international, randomized trial comparing i.v. enoxaparin with i.v. unfractionated heparin in primary PCI for ST-elevation myocardial infarction. G Montalescot (Paris, FR) • Discussant: H D White (Auckland, NZ)
  • ISAR REACT 3A: A trial of reduced dose of unfractionated heparin in patients undergoing percutaneous coronary interventions. S Schulz (Muenchen, DE) •  Discussant: C W Hamm (Bad Nauheim, DE)

31 Aug 2010

  • AVERROES: Apixaban versus acetylsalicylic acid (ASA) to prevent strokes.  S J Connolly (Hamilton, CA) •  Discussant: H Arnesen (Oslo, NO)
  • EINSTEIN DVT: Oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolism. H Buller (Amsterdam, NL) • Discussant: H Darius (Berlin, DE)
  • FUTURA OASIS 8: A randomised trial comparing two regimens of adjunctive intravenous unfractionated heparin during PCI in high-risk patients with non-STE-ACS treated with fondaparinux. S Jolly (Hamilton, CA) • Discussant: D Dudek (Krakow, PL)

Categories: General
Tags:


You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.